Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

Paul W. Hoelscher net worth and biography

Paul Hoelscher Biography and Net Worth

CFO of Horizon Therapeutics Public

Paul W. Hoelscher joined Horizon in June 2014. Before joining Horizon, he served as senior vice president, finance–treasury and corporate development of OfficeMax Inc., an office supply company, from Aug. 2013 to June 2014, and as vice president, finance–treasury and corporate development from Aug. 2012 to July 2013.

Hoelscher held various financial leadership roles during a 19-year career at Alberto Culver Company, a beauty care company, including serving as vice president, finance integration following Unilever's 2011 acquisition of Alberto Culver, as well as roles leading accounting, treasury and international finance from 1993 to 2012. Previously, he served in various positions of increasing responsibility in the audit practice at KPMG LLP from 1986 to 1993.

Hoelscher currently serves on the board of trustees of the Illinois Chapter of the Leukemia and Lymphoma Society. He received his Bachelor of Science in accountancy from the University of Illinois at Urbana-Champaign and is a certified public accountant.

What is Paul W. Hoelscher's net worth?: The estimated net worth of Paul W. Hoelscher is at least $121,998.70 as of April 20th, 2022. Mr. Hoelscher owns 1,049 shares of Horizon Therapeutics Public stock worth more than $121,999 as of April 20th. This net worth estimate does not reflect any other investments that Mr. Hoelscher may own. Learn More about Paul W. Hoelscher's net worth.
How do I contact Paul W. Hoelscher?: The corporate mailing address for Mr. Hoelscher and other Horizon Therapeutics Public executives is 1 BURLINGTON ROAD CONNAUGHT HOUSE 1ST FLOOR, Dublin L2, D04 C5Y6. Horizon Therapeutics Public can also be reached via phone at (531) 772-2100 and via email at [email protected]. Learn More on Paul W. Hoelscher's contact information.
Has Paul W. Hoelscher been buying or selling shares of Horizon Therapeutics Public?: Paul W. Hoelscher has not been actively trading shares of Horizon Therapeutics Public during the last quarter. Learn More on Paul W. Hoelscher's trading history.
Who are Horizon Therapeutics Public's active insiders?: Horizon Therapeutics Public's insider roster includes Brian Beeler (EVP), Daniel Camardo (EVP), Sean Clayton (EVP), Aaron Cox (CFO), Geoffrey Curtis (EVP), William Daniel (Director), Michael Desjardin (EVP), Michael Grey (Director), Paul Hoelscher (CFO), Vikram Karnani (EVP), Jeff Kent (Insider), Irina Konstantinovsky (EVP), Miles Mchugh (SVP), Barry Moze (EVP), Andy Pasternak (EVP), Jeffrey Sherman (EVP), Elizabeth Thompson (EVP), and Timothy Walbert (CEO). Learn More on Horizon Therapeutics Public's active insiders.

Paul W. Hoelscher Insider Trading History at Horizon Therapeutics Public

Paul W. Hoelscher Buying and Selling Activity at Horizon Therapeutics Public

Horizon Therapeutics Public Company Overview

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with HemoShear Therapeutics, LLC; Alpine Immune Sciences, Inc.; Halozyme Therapeutics, Inc.; Arrowhead Pharmaceuticals, Inc.; Q32 Bio Inc.; and Xeris Biopharma Holdings, Inc. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland.

Today's Range

Now: $116.30

$116.30

50 Day Range

MA: $115.72

$112.60

$116.30

2 Week Range

Now: $116.30

$60.03

$116.38

Volume

N/A

Average Volume

2,498,525 shs

Market Capitalization

$26.63 billion

P/E Ratio

62.19

Dividend Yield

N/A

Beta

1.03